Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.
Crystal Structure of the Kinase Domain of ABL in Complex with a Potent Rationally-Designed Derivative of the PP1 Inhibitor, AB129
Henderson, M. Nidanie, Kathryn E Malecek, Deborah L Makino, Xiaoxian X Cao, Kevan M Shokat, and John Kuriyan. “Crystal Structure of the Kinase Domain of Abl in Complex with a Potent Rationally-Designed Derivative of the Pp1 Inhibitor, Ab129.” Biophysical Journal 102, no. 3 (2012).
Crystallization of the Abl Kinase Domain with Combi-Inhibitors, ZRF1 and ZRF2
Amaefuna, Steve C.E, Angela M Harrington, Bertrand Jean-Claude, Bhushan Nagar, and M. Nidanie Henderson. “Crystallization of the Abl Kinase Domain with Combi-Inhibitors, Zrf1 and zrf2.” Biophysical Journal: Supplement 1 102, no. 3 (2012): 61
High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases
Seeliger, Markus A, Matthew Young, M. Nidanie Henderson, Patricia Pellicena, David S King, Arnold M Falick, and John Kuriyan. “High Yield Bacterial Expression of Active C-Abl and C-Src Tyrosine Kinases.” Protein Science 14, no. 12 (2005): 3135–39.
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty
Seeliger, M. A., Nagar, B., Frank, F., Cao, X., Henderson, M. N., & Kuriyan, J. (2007). "C-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty." Structure, 15(3), 299-311.